MedTrace Logo

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

NCT00002763 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2011-11-16

No results posted yet for this study

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III melanoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of high- or low-dose interferon alfa with that of no further therapy following surgery in treating patients who have stage III melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

recombinant interferon alfa

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Alexander M. M. Eggermont, MD, PhD · Daniel Den Hoed Cancer Center at Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-04-30

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Estonia
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Serbia
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002763 on ClinicalTrials.gov